MAP2 and Alzheimer disease: Likewise, NLY01 increases MAP2 And BDNF levels in 3xTg-AD mice [32], and a GLP1/GIP/glucagon triagonist elevates synaptophysin and PSD95 expression, while reducing pyramidal neuron over-excitability in 3xTg-AD hippocampal slices [53].